Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.06 | 0.00 | 0.04 |
| FCF Yield | -6.47% | -182.38% | 2,277.28% | 54.96% |
| EV / EBITDA | 54.19 | -19.44 | -0.61 | -1.19 |
| Quality | ||||
| ROIC | -7.33% | -12.49% | 100.70% | 14.58% |
| Gross Margin | 59.51% | 54.15% | 94.47% | 86.84% |
| Cash Conversion Ratio | -0.40 | -8.75 | 1.06 | 2.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -71.51% | 42.99% | 328.62% | 30.52% |
| Free Cash Flow Growth | 96.45% | -108.02% | 4,061.01% | 1,136.23% |
| Safety | ||||
| Net Debt / EBITDA | 161.08 | -22.96 | -0.65 | -4.08 |
| Interest Coverage | -241.91 | -368.72 | 6,189.44 | 148.41 |
| Efficiency | ||||
| Inventory Turnover | 1.30 | 3.79 | 2.86 | 0.63 |
| Cash Conversion Cycle | 613.49 | 234.83 | 125.83 | 590.15 |